Back PHARMACODYNAMIC AND PHARMACOKINETIC NEOADJUVANT STUDY OF HEDGEHOG PATHWAY INHIBITOR SONIDEGIB (LDE-225) IN MEN WITH HIGH-RISK LOCALIZED PROSTATE CANCER UNDERGOING PROSTATECTOMY Wednesday, July 26, 2017 Read the Story Here Share Related Posts Discover more posts like this. A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma Mar 6, 2024 Douglass Orr, MD A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors Mar 6, 2024 Minal Barve, MD PHASE 1 FIRST-IN- HUMAN STUDY OF DALUTRAFUSP ALFA, Cluster of differentiation (CD)73-adenosine and transforming growth factor (TGF)-β pathways are involved in abrogated antitumor immune responses and can lead to protumor conditions.... Jul 26, 2023 See All Posts